Complement factor H (Cfh) is a key plasma protein in humans and animals that serves to limit alternative pathway complement activation in plasma, as well as in local sites such as capillaries of the glomerulus and eye. It was shown that rodent Cfh on platelets is the functional analogue to human erythrocyte complement receptor 1 with a role that is distinct from plasma Cfh and that Cfh is also on cultured rodent podocytes. For investigation of the role of Cfh in the kidney, renal transplants were performed between wild-type (WT) and Cfh Ϫ/Ϫ C57BL/6 mice. For these studies, bilateral native nephrectomies were done so that renal function was dependent solely on the transplanted kidney. Chronic serum sickness was induced by active immunization with apoferritin. Diffuse proliferative glomerulonephritis (GN) occurred in WT kidneys that were transplanted into Cfh Ϫ/Ϫ recipients (n ‫؍‬ 8) but not into WT recipients (n ‫؍‬ 14), consistent with the importance of plasma Cfh to dictate outcome in this disease model. Relative to the WT recipients of WT kidneys, WT mice with Cfh Ϫ/Ϫ kidneys (n ‫؍‬ 12) developed glomerular disease features, including increased albuminuria (82.8 ؎ 7.0 versus 45.1 ؎ 3.6 g/mg creatinine; P < 0.001) and blood urea nitrogen levels (54.4 ؎ 6.1 versus 44.2 ؎ 3.7 mg/dl; P < 0.01). In addition, they had substantial glomerular capillary wall deposits of IgG and C3, which by electron microscopy were present in subendothelial and subepithelial immune deposits, whereas WT kidneys in WT hosts had almost exclusive mesangial deposits. The IgG deposits in Cfh Ϫ/Ϫ kidneys were adjacent to Cfh-deficient podocytes, whereas WT kidneys in a Cfh Ϫ/Ϫ host had podocyte-associated Cfh with absent IgG deposits. These data suggest that locally produced podocyte Cfh is important to process immune complexes in the subepithelial space, where it also limits complement activation. Just as in platelets, rodent podocytes seem to use Cfh as the functional surrogate for human complement receptor 1.
T he complement system is a powerful component of innate immunity that recognizes and facilitates the elimination of pathogens and unwanted host material (1) . The classical, alternative, and lectin activation pathways converge to form C3/C5 convertases that generate C3a, C3b, C5a, and C5b, each with substantial biologic activity. Complement regulators are necessary to prevent the injudicious production of these mediators and potential injury to self-tissue (2, 3) . The plasma proteins complement factor H (Cfh) and C4-binding protein and the cell membrane proteins complement receptor 1 (CR1; CD35), decay-accelerating factor (CD55), and membrane co-factor protein (CD46) all are members of the regulators of complement activation gene family on chromosome 1q32 in humans and a comparable genomic location in mice (4 -6) . These proteins have natural affinity for C3b and/or C4b, which confers on them the ability to accelerate the intrinsic decay of C3/C5 convertases and/or act as co-factor for the cleavage and inactivation (i) of C3b and C4b by complement factor I (Cfi) (3) .
Complement is also crucial for the proper disposal of immune complexes (IC). This multistep process requires complement activation by IC Ig, leading to their incorporation of C3b, which binds to cells that bear specific immune adherence receptors (IAR) (7) . Although it is clear that primates use the erythrocyte and its CR1 protein for this function, other species, such as the mouse, rely on platelets to process IC (8) . IC that are bound to erythrocyte or platelet IAR are transported to CR3-and Fc␥R-bearing cells of the mononuclear phagocyte system for elimination (9, 10) . We have shown that the platelet protein that is responsible for binding C3b in IC is Cfh (11) ; as with CR1 in humans, platelet Cfh has three essential features: (1) It is on the membrane of a ubiquitous blood cell, (2) it has binding affinity for C3b, and (3) it serves as a Cfi co-factor for the cleavage of C3b to iC3b.
The glomerular podocyte is also capable of IA (12) . In humans, the podocyte IAR is CR1 as it is on erythrocytes (13) . Notably, CR1 protein quantities are decreased on both erythrocytes and podocytes in IC diseases such as systemic lupus erythematosus (14, 15) , which is attributable to loss of the entire CR1 molecule and not just its extracellular domain (16) . CR1 is also produced as a soluble urinary form that retains its IC-binding capacity (17) . Despite a significant amount of data on its appearance in normal and diseased states, the roles for human podocyte CR1 are unknown, as is the identity of its analogue in the rodent.
Given these different functions of Cfh, we studied an active model of chronic serum sickness (CSS) that lead to glomerular IC disease in which IC processing and complement activation are key. In this model, platelet Cfh is necessary for proper IC processing, whereas plasma Cfh is of primary importance to dictate disease outcome (18, 19) . Here we continued our studies with this active IC model by concentrating on intrinsic glomerular Cfh through the transplantation of Cfh-sufficient and -deficient kidneys. As in previous studies, plasma Cfh proved to be a key factor protecting against development of IC glomerulonephritis (ICGN) in C57BL/6 mice, because its absence resulted in glomerular inflammation. Cfh seems to be on the podocyte in place of CR1, where it can limit complement activation and facilitate glomerular IC processing.
Materials and Methods

Animals
Normal wild-type (WT) C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). Cfh Ϫ/Ϫ mice were generated and provided by Drs. Matthew Pickering and Marina Botto (20) . Mice were backcrossed Ͼ10 generations onto the C57BL/6 strain. Genotyping of mice was performed by PCR using genomic DNA and primers 5Ј-GTAAAGGTCCTCCTCCAAGAG-3Ј (Cfh), 5Ј-GGTATAAACAACCTT-TGCACC-3Ј (Cfh), and 5Ј-GGGGATCGGCAATAAAAAGAC-3Ј (Neo), at 1:2:0.5 ratios and 55°C annealing temperatures. Products of 576 and 500 bp were generated from WT and knockout alleles, respectively. Western blotting was used to confirm the absence of plasma Cfh in all Cfh Ϫ/Ϫ mice. All studies were approved by the University of Chicago
Institutional Animal Care and Use Committee.
Renal Transplant Protocol
Kidneys were transplanted between male WT and Cfh Ϫ/Ϫ mice as described previously (21, 22) . All mice were Ͻ9 wk of age, at which time there are no histologic abnormalities in Cfh Ϫ/Ϫ mice (20) . After anesthesia with 65 mg/kg intraperitoneal pentobarbital, the left kidney of donor mice was perfused via the renal artery with 0.3 ml of cold saline; resected with artery, vein, and ureter attached; and stored at 4°C until time of anastomoses. The recipient underwent midline abdominal incision followed by suprarenal clamping of aorta and inferior vena cava. The donor kidney was placed in the right flank, and its artery and vein were attached with 10-0 nylon suture via side-to-end anastomoses with the recipient aorta and inferior vena cava. Total cold ischemic time was typically Ͻ45 min and never Ͼ1 h. The bladder was punctured with a 21-G needle, and the ureter was sewn in place. Because of the desire to rely solely on the transplanted kidney for renal function, both native kidneys were removed before generation of CSS. Given a mild degree of reperfusion injury, one native kidney was resected at the time of transplant. Between 10 and 14 d later, the remaining native kidney was resected, at which time the transplanted kidney was also inspected. Mice were excluded from the study for technical reasons or operative or spontaneous mortality (Ͻ10% of all mice met these criteria).
Short-Term Studies
Initial experiments were performed to evaluate acute events that occurred in kidneys that were transplanted between Cfh Ϫ/Ϫ and WT mice. Studied were WT kidneys that were transplanted into Cfh Ϫ/Ϫ or WT hosts and Cfh Ϫ/Ϫ kidneys that were transplanted into WT hosts (n ϭ 4 per group). In half of the mice, a biopsy was taken 5 min after transplantation, followed in 10 min by killing of the mouse. In the others, a biopsy was taken at 10 min and the animal was killed after 30 min. Kidney tissue was processed for the phenotypic analyses described next.
CSS
To induce CSS in which circulating IC can deposit in glomeruli and lead to GN, mice with renal transplants were immunized with a daily intraperitoneal dose of 4 mg of horse spleen apoferritin (Calzyme Laboratories, San Luis Obispo, CA) (19, (23) (24) (25) ; controls were treated identically with saline vehicle only. Mice that received apoferritin were WT mice with WT kidneys (n ϭ 14), WT mice with Cfh Ϫ/Ϫ kidneys (n ϭ 12), and Cfh Ϫ/Ϫ mice with WT kidneys (n ϭ 8). Mice that received saline were WT mice with WT kidneys (n ϭ 5), WT mice with Cfh Ϫ/Ϫ kidneys (n ϭ 3), and Cfh Ϫ/Ϫ mice with WT kidneys (n ϭ 3). After 5 wk of immunization, the study was terminated. Because studies required assessment of local Cfh, the renal artery was perfused with saline, after which cortex from the transplanted kidney was immediately harvested and the animal was killed.
Measurements of Blood Urea Nitrogen and Urinary Albumin
Blood urea nitrogen (BUN) and urinary creatinine concentrations were detected with a Beckman Autoanalyzer (Beckman Coulter, Fullerton, CA). In unmanipulated WT mice, BUN values are 22.8 Ϯ 5.8 mg/dl (mean Ϯ SD; n ϭ 42) (26), which correlate in normal and diseased animals with serum creatinine levels (27) . Consistent with our previous data that mice that rely solely on a transplanted kidney have a mild and stable elevation in BUN and serum creatinine levels (21, 22) , kidney transplant recipients in this study had mean and median BUN values of 26.5 and 26.6 mg/dl, respectively, and no values Ͼ35 mg/dl.
Urinary albumin concentrations were measured with a mouse albumin ELISA kit (Bethyl Laboratories, Montgomery, TX) and expressed relative to urinary creatinine (g/mg), as described previously (28) . Normal mice excrete Ͻ25 g albumin/mg creatinine, which is unaffected by chronic saline administration (19, 28) . Mice with CSS induced by apoferritin develop modest albuminuria; in past studies, this has ranged from 29.3 Ϯ 3.5 to 58.7 Ϯ 11.1 g albumin/mg creatinine (19, 28) .
Western Blots
A small portion of renal cortex from transplanted kidneys was solubilized in 150 mM sodium chloride, 1% NP-40, 50 mM Tris (pH 8.0), and protease inhibitor cocktail (Roche Molecular Biochemicals, Pleasanton, CA). Equivalent amounts of protein or volumes of sera were separated by SDS-PAGE (10%), transferred onto polyvinylidine difluoride membranes (Millipore, Bedford, MA), and incubated with goat anti-human Cfh (Quidel, San Diego, CA) followed by horseradish peroxidase-anti-goat IgG (Sigma-Aldrich, St. Louis, MO). Bound antibodies were detected with enhanced chemiluminescence (Pierce Biotechnology, Rockford, IL). On the basis of our previous studies, this anti-human Cfh antibody cross-reacts with both rat and mouse Cfh (11, 18, 29) , as well as rat factor H-related protein (30) , consistent with the relatedness of the various proteins within and between species (31, 32) .
Immunofluorescence Microscopy
washed with PBS, and stained with FITC-conjugated goat antibodies to mouse IgG or C3 (Cappel Pharmaceuticals, Aurora, OH). Slides were viewed with an Olympus BX-60 IF microscope (Melville, NY). Individual staining intensity scores from 0 to 4 were assigned to both mesangial and glomerular capillary wall (GCW) staining individually. In addition, staining of the basolateral aspects of renal tubules and around Bowman's capsule for C3 was evaluated (33) . Scores were accumulated by two observers (A.C. and R.J.Q.), who were masked to the origin of the slides, and averaged. Photomicrographs that were representative of the staining patterns and intensities were taken at identical settings.
Triple staining for IgG, Cfh, and ␣-actinin 4 to identify podocytes (34) was performed by immunofluorescence (IF). The former two were directly detected with Alexa 594 conjugated to anti-Cfh according to the manufacturer's instructions and Alexa 350 anti-mouse IgG (Invitrogen, Carlsbad, CA). Anti-␣-actinin 4 was detected with an affinity-purified rabbit IgG antibody to a synthetic peptide that contained amino acids 29 to 39 of mouse ␣-actinin 4 (Alexis, Lausen, Switzerland), followed by Alexa 488 anti-rabbit IgG (not reactive with mouse IgG; Invitrogen). Images were acquired with an Olympus IX-81 confocal microscope and merged using Photoshop CS2 software (Adobe, San Jose, CA).
Renal Pathology
Tissues were fixed in 10% buffered formalin and embedded in paraffin, from which 4-m-thick sections were cut and stained with periodic acid-Schiff. In specimens from mice with CSS, slides were scored in a blinded manner by a renal pathologist (M.H.) for the extent of GN on a scale of 0 to 4 (in increments of 0.5) according to the schema of Passwell et al. (35) as described previously (18, 19) . In short-term studies after renal transplantation, the presence of epithelial cell necrosis and neutrophil infiltration was also sought using previously published protocols (33) .
Ultrastructural features were also examined in glomeruli from several randomly chosen mice from each of the experimental groups. Renal cortex was processed for electron microscopy using standard techniques as described previously (28) . Sections were viewed with a Philips CM10 electron microscope (Bothell, WA), and representative photographs were taken.
Statistical Analyses
Data are presented as means Ϯ SEM and were analyzed using Minitab software (version 12; College Park, MD). Statistical significance between groups was determined by 2 analysis or ANOVA followed by Fisher pairwise tests.
Results
Acute Effects of Renal Transplantation in Cfh Ϫ/Ϫ Mice
In normal mouse kidneys, C3 staining is evident along the basement membranes of Bowman's capsule and renal tubules (28) ; this can be attributed to alternative pathway activation, which can be enhanced in warm ischemia-reperfusion injury (36, 37) . Despite absent systemic alternative pathway complement regulatory activity, unmanipulated Cfh Ϫ/Ϫ mice lack this typical C3 staining (19) , yet Cfh Ϫ/Ϫ mice have substantial glomerular deposition of IgG and C3 (20) . Because of the abrupt exposure of transplanted kidneys to plasma, particularly Cfh Ϫ/Ϫ kidneys that were exposed to normal plasma and WT kidneys to Cfh Ϫ/Ϫ plasma, studies were performed to analyze acute events in transplanted kidneys. In these, there were no significant changes in glomerular IgG and C3 immunostaining compared with baseline up to 30 min after establishment of blood flow in the transplanted kidneys. Specifically, WT glomeruli had modest amounts of IgG (0 to 1ϩ) in the mesangium and absent C3 ( Figure 1 , A and C, respectively), whereas Cfh Ϫ/Ϫ glomeruli had significant quantities of IgG and C3 (1 to 3ϩ) in the mesangium and GCW ( Figure 1 , B and D, respectively). Small amounts of discontinuous staining for C3 became apparent around tubules of Cfh Ϫ/Ϫ mice within 30 min after transplantation into a WT host ( Figure 1E ), yet from a histologic standpoint, this did not seem to be of significance, because there was only mild accumulation of periodic acid-Schiff-positive material in tubular lumina and no epithelial cell necrosis or neutrophil infiltration in any of the 4 Cfh Ϫ/Ϫ kidneys that were transplanted into WT hosts that were evaluated from 5 to 30 min after transplantation ( Figure 1G ). Comparable findings were observed in WT kidneys that were transplanted into Cfh Ϫ/Ϫ and WT hosts ( Figure 1F ).
Systemic Cfh Dictates Outcome in ICGN
Mice with renal transplants were studied after 5 wk of daily immunization with apoferritin or with saline as controls. The potential for the transplanted kidney to contribute to the local and systemic pool of Cfh was first evaluated. Cfh was apparent in sera of WT hosts with Cfh Ϫ/Ϫ kidneys but not in Cfh Ϫ/Ϫ mice with WT kidneys (Figure 2A) , illustrating that the kidneys did not contribute substantially to systemic Cfh pools. Cfh Ϫ/Ϫ kidneys in a WT host had small amounts of Cfh ( Figure 2B ), which could reflect that plasma Cfh remained after perfusion, Cfh bound to tissue sites such as the GCW (38) , and/or Cfh that was produced from host-derived hematopoeitic cells in the transplanted kidney. WT kidneys in a Cfh Ϫ/Ϫ host had faintly detectable Cfh ( Figure 2B ), which is consistent with localized renal production of Cfh (addressed in the next section). Also of importance from these studies using anti-Cfh antibodies are the absence of alternative forms of Cfh in Cfh Ϫ/Ϫ serum or kidneys, such as Cfh-like or related proteins that can have complement regulatory activity (30, 32, 39, 40) . WT kidneys that were transplanted into Cfh Ϫ/Ϫ mice and followed by induction of CSS uniformly developed diffuse proliferative GN ( Figure 3B ), with features identical to those that were seen in previous studies in Cfh Ϫ/Ϫ mice with this model (18, 19) . Along with histologic findings of GN was evidence for functional renal disease, as assessed by measurements of BUN (Table 1) . WT hosts with WT kidneys in which CSS was induced had largely normal histology and renal function ( Figure 3A ). These data continue to affirm the clear importance of plasma Cfh to dictate outcome in this model, with normal C57BL/6 mice being resistant to GN (18, 19 Figure 3C ). In these mice, the extent of albuminuria was higher than in any other group (Table 1) . Thus, locally produced Cfh seems to limit CSS disease manifestations that occur in the GCW and podocyte. In all control transplanted groups (WT kidneys in WT and Cfh Ϫ/Ϫ mice and Cfh Ϫ/Ϫ kidneys in WT mice) that received saline instead of apoferritin, renal function and histology were normal (data not shown).
Role of Cfh in IC Processing and Complement Activation in Kidneys
IF microscopy was performed for IgG and C3 from all transplanted kidneys in hosts that had received apoferritin or saline for 5 wk (Figure 4) . Staining scores for mesangial and GCW IgG and C3 were also compared with scores that were obtained 30 min after reperfusion and presented graphically in Figure 4 , K and L, to illustrate changes after transplantation. WT kidneys in WT hosts with CSS had significant mesangial deposits of IgG and C3 with minimal extension to the GCW (Figure 4 , A and F), which were absent in similar mice that received saline. Cfh Ϫ/Ϫ mice that received WT kidney transplants and were given saline as controls had mild accumulation of IgG in the mesanigum but not in the GCW ( Figure 4B ) and more intense mesangial C3 staining with segmental extension to the GCW (Figure 4G) , whereas this group of mice with CSS had accentuated staining for IgG and C3 with IgG extending in some mice to segmental areas of the GCW (Figure 4, C and H) . Cfh Ϫ/Ϫ kidneys that were transplanted into a WT host began with substantial mesangial and GCW staining for IgG and C3 (cf, Figure  1 C3 staining of tubular and Bowman's capsular basement membranes was also evaluated in these studies. The presence or absence of this C3 staining was simply dictated by the Cfh status of the host, while not being affected to an appreciable extent by the CSS protocol. Thus, after 5 wk, Cfh Ϫ/Ϫ kidneys that were transplanted into WT hosts had discontinuous linear staining for C3 around tubules and glomeruli ( Figure 4I ), whereas this staining became absent in WT kidneys in a Cfh Ϫ/Ϫ host ( Figure 4G ). These data show that Cfh Ϫ/Ϫ kidneys-but not WT kidneys-that were transplanted into WT hosts and followed by induction of CSS developed substantial GCW deposits of IgG and C3, as well as C3 staining around tubules and glomeruli. In fact, each of the six groups (WT kidneys in WT or Cfh Ϫ/Ϫ hosts, and Cfh Ϫ/Ϫ kidneys in WT hosts, receiving either saline or apoferritin over 5 wk) had a distinct combination of IgG and C3 staining patterns in the anatomic compartments evaluated. These patterns seen from IF staining were confirmed ultrastructurally with electron microscopy. Thus, electron-dense deposits were exclusively present in the mesangium of WT kidneys in WT hosts with CSS. In contrast, electron-dense deposits extended to both subendothelial and subepithelial sites in Cfh Ϫ/Ϫ kidneys in WT hosts with CSS, as shown in Figure 5 from three separate kidneys.
Cfh in Mice Is Analogous to Human Podocyte CR1
There were apparent differences in intraglomerular IC processing between Cfh Ϫ/Ϫ and WT kidneys, despite each being present in a WT host with intact systemic Cfh. To investigate the potential that Cfh is intrinsic to the glomerulus where it could affect IC processing, we performed IF microscopy for Cfh and IgG, along with ␣-actinin 4 as a podocyte marker. WT kidneys in a Cfh Ϫ/Ϫ host had significant staining for Cfh in the GCW ( Figure 6A ). Consistent with previous data, glomeruli from these mice had IgG localized to the mesangium, as well as some segments of the GCW ( Figure 6B ). Staining for ␣-actinin 4 in the same specimen ( Figure 6C ) confirmed that IgG was largely in mesangial regions ( Figure 6D ), whereas Cfh was consistently present in the same regions as ␣-actinin 4 ( Figure  6E ). Cfh Ϫ/Ϫ kidneys in a WT host had small amounts of Cfh in the mesangium ( Figure 6F ) and mesangial and GCW staining for IgG ( Figure 6G ). The latter was accumulated adjacent to podocytes that lacked Cfh ( Figure 6 , 1 and J, arrows). Taken together, the data from this study suggest that Cfh is an intrinsic protein on the podocyte, on which it is important to limit complement activation and process IC that traverse the GCW. By analogy to the mouse platelet, Cfh is likely to represent the mouse analogue to human podocyte CR1.
Discussion
The relevance of complement activation to many immunemediated human glomerular diseases seems likely and has been supported by observational studies in humans and intense work in experimental animals (41, 42) . Cfh is key to effective regulation of the otherwise active complement alternative pathway; abnormalities in Cfh quantity or function result in uncontrolled alternative pathway activation (40, 43) . The potency of the complement alternative pathway and its potential to result in glomerular diseases such as membranoproliferative GN (MPGN) (44) , IgA nephropathy (45) , and lupus nephritis (46, 47) are becoming more entrenched with time (48) . For instance, genetic abnormalities in Cfh are associated with spontaneous MPGN type II in humans and pigs (49 -51) . Mice with targeted deletion of Cfh have marked systemic alternative pathway complement activation and develop glomerular disease with features of human MPGN type II later in life, with fatal renal failure in some animals (20) . In these animals, complement deposition in the GCW (a feature of MPGN type II) precedes IC deposition (a feature of MPGN type I but not type II). As predicted, the glomerular disease phenotype depends on the alternative pathway, as shown by its absence in Cfh Ϫ/Ϫ mice with coexisting complement factor B deficiency (20) . Furthermore, elevated serum creatinine, MPGN histopathologic features, and neutrophil infiltration of glomeruli depend, at least in part, on C5 activation in Cfh Ϫ/Ϫ mice (52).
Unlike some strains, C57BL/6 mice are resistant to developing glomerular inflammation in apoferritin-induced CSS (19, 24, 25) . This is despite the development of a strong humoral immune response to the immunogen and the deposition of IC and complement activation products in glomeruli. However, in our previous studies, all C57BL/6 Cfh Ϫ/Ϫ mice with CSS developed GN (19) . Thus, Cfh deficiency converts the C57BL/6 strain from one that is resistant to GN into one that is susceptible to GN. Arguably, the most important function for Cfh is its ability to limit complement activation in plasma and in sites that are not served by other complement regulators, such as the GCW and choroidal capillaries (53) . However, it is a versatile protein with a number of other functions, such as its serving as the platelet protein responsible for IC processing in rodents (11) . In our follow-up studies using bone marrow chimeric mice, we showed that the roles for plasma and platelet Cfh were separable (18) . Plasma Cfh limits complement activation in the circulation and other accessible sites such as the glomerulus, whereas platelet Cfh is responsible for IC processing. In a disease such as CSS, IC deposition and complement activation occur in glomeruli, yet C3b is efficiently inactivated to iC3b when Cfh is present in plasma to serve as Cfi co-factor; this is operative even when excessive IC deposition occurs in glomeruli, such as when platelet Cfh is absent (54) . In this study, CSS induced in Cfh Ϫ/Ϫ but not WT recipients of a WT kidney led to histologic manifestations of GN and impaired function of the transplanted kidney. These data affirm the relevance of plasma Cfh to IC-mediated GN in C57BL/6 mice. Rodent platelets and megakaryocytes have the capacity to produce Cfh and display it on their membranes (11, 18) . Thus, rodents have adapted to use Cfh to function on platelets in place of CR1 on erythrocytes; this is sensible, given that the two have a high degree of structural and functional relatedness. Similar to platelets, cultured rat podocytes can produce Cfh and have it remain membrane associated (29) . Our results from WT kidneys that were transplanted into Cfh Ϫ/Ϫ hosts provide compelling data that mouse podocytes produce Cfh in vivo. In this setting, there is absent plasma Cfh and only small quantities of total renal Cfh, yet Cfh in glomeruli is closely associated with the podocyte ␣-actinin 4 protein, present in their "soles" adjacent to the glomerular basement membrane (55) . Particularly because Cfh lacks a membrane-spanning region, whether it is an intrinsic podocyte membrane protein such as CR1 or is just in the vicinity of the podocyte cell membrane cannot be stated for certainty. Impaired glomerular IC processing occurred when extrarenal or podocyte-associated Cfh was absent.
In the former condition, this can be attributed to some combination of absent platelet Cfh, absent plasma Cfh, and acquired hypocomplementemia, each of which is relevant to proper glomerular IC handling (18, 28, 56) . In the instance in which local glomerular Cfh was absent, the explanation for the presence of GN, albuminuria, and GCW deposits is less obvious. It is known that an intact complement system is necessary for the directed movement of IC across the GCW (57) . Our data suggest that intrinsic podocyte-associated Cfh is also required for this orderly processing of IC. Exactly how this occurs and whether mouse Cfh is analogous to human podocyte CR1 are the subject of ongoing investigation. That IC were persistent in the subendothelial and subepithelial locations does provide a compelling explanation for GN and albuminuria, respectively. There is also the potential that intrinsic Cfh supplements the complement regulatory effects of podocyte decay-accelerating factor to limit these glomerular disease features (58) . The presence of C3 in the basement membranes of tubules and Bowman's capsule has been assumed to occur from alternative complement activation (37) , which was subsequently proved in studies with C3-and factor B-deficient mice (28, 36) . This alternative pathway complement activation on tubules is postulated to be relevant to acute and chronic human renal diseases (59, 60) . In mouse kidneys that are reperfused after warm ischemia, alternative pathway complement activation occurs (36) . This can be attributed to loss of intrinsic tubular CR1-related protein y (Crry), which is a key cell-associated complement regulatory protein; in a relatively short period of time, Crry is regenerated by tubules, leading to their recovery (61) . It is interesting that C3 activation products were absent on the basolateral aspects of tubules in Cfh Ϫ/Ϫ mice yet started to form quickly upon exposure to plasma from a normal mouse in our transplant studies. This is not from local C3 production (62), because WT kidneys in Cfh Ϫ/Ϫ mice lost this over time.
Hence, activation of C3 onto the basolateral aspects of tubules requires an intact systemic alternative pathway, including its main regulator, Cfh. Taking together the data from this study and our related previous studies (18, 19) , WT C57BL/6 mice with apoferritininduced CSS develop circulating IC that can aggregate in glomerular sites. Glomerular accumulation of IC is substantially limited by platelets that bear Cfh, which presumably present IC to the mononuclear phagocyte system. In addition, Cfh on the podocyte is important for the directed movement of IC through the GCW and also may serve as one of its intrinsic complement regulators. Plasma Cfh limits complement activation that is initiated by IC in the GCW and potentially the mesangium, thereby preventing the generation of proinflammatory complement activation products. It is the composition and location of these complement activation products that ultimately influence the outcome of IC-mediated glomerular diseases (63) .
